node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
ADORA3 | ADRA2A | ENSP00000358730 | ENSP00000280155 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | 0.953 |
ADORA3 | CNR1 | ENSP00000358730 | ENSP00000358513 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Cannabinoid receptor 1; G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP. In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agon [...] | 0.952 |
ADORA3 | OPRD1 | ENSP00000358730 | ENSP00000234961 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Delta-type opioid receptor; G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. [...] | 0.950 |
ADORA3 | OPRK1 | ENSP00000358730 | ENSP00000265572 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Kappa-type opioid receptor; G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by r [...] | 0.949 |
ADORA3 | OPRL1 | ENSP00000358730 | ENSP00000336764 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Nociceptin receptor; G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception [...] | 0.953 |
ADORA3 | OPRM1 | ENSP00000358730 | ENSP00000394624 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Mu-type opioid receptor; Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell typ [...] | 0.950 |
ADORA3 | P2RY12 | ENSP00000358730 | ENSP00000307259 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | P2Y purinoceptor 12; Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation; P2Y receptors | 0.968 |
ADORA3 | P2RY13 | ENSP00000358730 | ENSP00000320376 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | P2Y purinoceptor 13; Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system; P2Y receptors | 0.966 |
ADORA3 | P2RY14 | ENSP00000358730 | ENSP00000308361 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | P2Y purinoceptor 14; Receptor for UDP-glucose and other UDP-sugar coupled to G-proteins. Not activated by ATP, ADP, UTP or ATP; P2Y receptors | 0.955 |
ADORA3 | P2RY4 | ENSP00000358730 | ENSP00000363643 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | P2Y purinoceptor 4; Receptor for UTP and UDP coupled to G-proteins that activate a phosphatidylinositol-calcium second messenger system. Not activated by ATP or ADP | 0.956 |
ADRA2A | ADORA3 | ENSP00000280155 | ENSP00000358730 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | 0.953 |
ADRA2A | CNR1 | ENSP00000280155 | ENSP00000358513 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | Cannabinoid receptor 1; G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP. In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agon [...] | 0.962 |
ADRA2A | OPRD1 | ENSP00000280155 | ENSP00000234961 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | Delta-type opioid receptor; G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. [...] | 0.928 |
ADRA2A | OPRK1 | ENSP00000280155 | ENSP00000265572 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | Kappa-type opioid receptor; G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by r [...] | 0.928 |
ADRA2A | OPRL1 | ENSP00000280155 | ENSP00000336764 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | Nociceptin receptor; G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception [...] | 0.928 |
ADRA2A | OPRM1 | ENSP00000280155 | ENSP00000394624 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | Mu-type opioid receptor; Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell typ [...] | 0.927 |
ADRA2A | P2RY12 | ENSP00000280155 | ENSP00000307259 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | P2Y purinoceptor 12; Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation; P2Y receptors | 0.928 |
ADRA2A | P2RY13 | ENSP00000280155 | ENSP00000320376 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | P2Y purinoceptor 13; Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system; P2Y receptors | 0.913 |
ADRA2A | P2RY14 | ENSP00000280155 | ENSP00000308361 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | P2Y purinoceptor 14; Receptor for UDP-glucose and other UDP-sugar coupled to G-proteins. Not activated by ATP, ADP, UTP or ATP; P2Y receptors | 0.911 |
ADRA2A | P2RY4 | ENSP00000280155 | ENSP00000363643 | Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol; Adrenoceptors | P2Y purinoceptor 4; Receptor for UTP and UDP coupled to G-proteins that activate a phosphatidylinositol-calcium second messenger system. Not activated by ATP or ADP | 0.914 |